The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders

Authors:

Shavlovskaya O.A.

More about the authors

Views: 1382

Downloaded: 1


To cite this article:

Shavlovskaya OA. Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):43‑47. (In Russ.)
https://doi.org/10.17116/jnevro202412406143

Recommended articles:
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Sleep diso­rders and onco­logical diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131
Fluvoxamine in the treatment of anxiety-depressive spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.